Trials / Recruiting
RecruitingNCT06375473
Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,000 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study is a multi-center observational study.The start time for data collection is May 1, 2024. Patients' baseline and treatment data will be collected under informed concent. The purpose of this case registry study was to evaluate the safety and efficacy of irinotecan hydrochloride liposome injection II based therapy in Chinese patients with pancreatic cancer in the real world by collecting, understanding, and analyzing the etiology, clinical features, treatment pattern, treatment outcomes, and pharmacoeconomics changes in pancreatic cancer patients receiving this regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irinotecan liposome II combination therapy regimen | Irinotecan liposome II combination therapy regimen |
Timeline
- Start date
- 2024-04-19
- Primary completion
- 2027-04-19
- Completion
- 2027-04-19
- First posted
- 2024-04-19
- Last updated
- 2026-01-06
Locations
10 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06375473. Inclusion in this directory is not an endorsement.